CY1121586T1 - Αντιοξειδωτικοι ρυθμιστες της φλεγμονης: παραγωγα ελαιανολικου οξεος με αμινικη και αλλες τροποποιησεις στο c-17 - Google Patents
Αντιοξειδωτικοι ρυθμιστες της φλεγμονης: παραγωγα ελαιανολικου οξεος με αμινικη και αλλες τροποποιησεις στο c-17Info
- Publication number
- CY1121586T1 CY1121586T1 CY20191100194T CY191100194T CY1121586T1 CY 1121586 T1 CY1121586 T1 CY 1121586T1 CY 20191100194 T CY20191100194 T CY 20191100194T CY 191100194 T CY191100194 T CY 191100194T CY 1121586 T1 CY1121586 T1 CY 1121586T1
- Authority
- CY
- Cyprus
- Prior art keywords
- acid derivatives
- olanic
- aminic
- regulators
- inflammation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/10—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
Abstract
Αυτή η εφεύρεση παρέχει, αλλά δεν περιορίζεται σε, νέα παράγωγα ελαιανολικού οξέος που έχουν τον τύπο: όπου οι μεταβλητές ορίζονται στο παρόν. Επίσης παρέχονται φαρμακευτικές συνθέσεις, κιτ αντικείμενα παρασκευής που περιλαμβάνουν αυτές τις ενώσεις, μέθοδοι και ενδιάμεσα προϊόντα χρήσιμα για την παρασκευή των ενώσεων και μέθοδοι χρήσης των ενώσεων και των συνθέσεων.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4634208P | 2008-04-18 | 2008-04-18 | |
US11126908P | 2008-11-04 | 2008-11-04 | |
PCT/US2009/041172 WO2009129546A1 (en) | 2008-04-18 | 2009-04-20 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121586T1 true CY1121586T1 (el) | 2020-05-29 |
Family
ID=40833485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100194T CY1121586T1 (el) | 2008-04-18 | 2019-02-13 | Αντιοξειδωτικοι ρυθμιστες της φλεγμονης: παραγωγα ελαιανολικου οξεος με αμινικη και αλλες τροποποιησεις στο c-17 |
Country Status (26)
Country | Link |
---|---|
US (8) | US8124799B2 (el) |
EP (1) | EP2276493B1 (el) |
JP (1) | JP5529851B2 (el) |
KR (1) | KR101735807B1 (el) |
CN (2) | CN104177468B (el) |
AU (1) | AU2009237579C1 (el) |
CA (1) | CA2721838C (el) |
CO (1) | CO6311071A2 (el) |
CY (1) | CY1121586T1 (el) |
DK (1) | DK2276493T3 (el) |
EA (1) | EA019263B1 (el) |
ES (1) | ES2703274T3 (el) |
HK (2) | HK1152483A1 (el) |
HR (1) | HRP20182060T1 (el) |
HU (1) | HUE041221T2 (el) |
IL (1) | IL208758A (el) |
LT (1) | LT2276493T (el) |
MX (1) | MX2010011438A (el) |
NZ (1) | NZ588710A (el) |
PL (1) | PL2276493T3 (el) |
PT (1) | PT2276493T (el) |
RS (1) | RS58392B1 (el) |
SI (1) | SI2276493T1 (el) |
TW (1) | TWI453023B (el) |
WO (1) | WO2009129546A1 (el) |
ZA (1) | ZA201007586B (el) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
PL1848414T3 (pl) | 2005-02-03 | 2011-10-31 | Wyeth Llc | Sposób leczenia nowotworu opornego na gefitinib |
PE20070763A1 (es) | 2005-11-04 | 2007-08-08 | Wyeth Corp | COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272 |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
CA3062806C (en) | 2008-01-11 | 2022-09-13 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
ES2326065B1 (es) * | 2008-03-28 | 2010-07-08 | Consejo Superior De Investigaciones Cientificas (Csic) | Utilizacion de un triterpeno pentaciclico para la preparacion de una composicion farmaceutica destinada al tratamiento de la esclerosis multiple. |
TWI442925B (zh) | 2008-04-18 | 2014-07-01 | Reata Pharmaceuticals Inc | 抗氧化性發炎調節劑:c-環飽和之齊墩果酸衍生物 |
CA2721665C (en) | 2008-04-18 | 2017-01-24 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
KR101782020B1 (ko) | 2008-04-18 | 2017-09-26 | 리타 파마슈티컬스 잉크. | 산화방지성 염증 조절제 c-17 일치된 올레아놀산 유도체 |
ES2703274T3 (es) | 2008-04-18 | 2019-03-07 | Reata Pharmaceuticals Inc | Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17 |
TW201004627A (en) | 2008-04-18 | 2010-02-01 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
AU2009274037B2 (en) | 2008-07-22 | 2015-07-09 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
CN102202667A (zh) | 2008-08-04 | 2011-09-28 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
MX356593B (es) | 2009-04-06 | 2018-06-05 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib para cáncer de mama. |
PL2558105T3 (pl) | 2010-04-12 | 2020-04-30 | Reata Pharmaceuticals, Inc. | Metylowany bardoksolon do leczenia otyłości |
EA025568B1 (ru) | 2010-12-17 | 2017-01-30 | Рита Фармасьютикалз, Инк. | Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления |
WO2012125488A1 (en) | 2011-03-11 | 2012-09-20 | Reata Pharmaceuticals, Inc. | C4-monomethyl triterpenoid derivatives and methods of use thereof |
MX2013013281A (es) * | 2011-05-16 | 2013-12-06 | Bayer Ip Gmbh | Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca. |
WO2013079024A1 (zh) * | 2011-12-01 | 2013-06-06 | 杭州本生药业有限公司 | 齐墩果酸酰胺化衍生物、及其制备方法和应用 |
RS61544B1 (sr) | 2012-04-27 | 2021-04-29 | Reata Pharmaceuticals Inc | Derivat 2,2-difluoropropionamida metil bardoksolona, njegove farmaceutske supstance i polimorfi za upotrebu za lečenje izvesnih stanja |
US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
MX2015003021A (es) * | 2012-09-10 | 2015-11-09 | Abbvie Inc | Derivados de acido glicirretinico y metodos de uso de los mismos. |
WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
LT2892912T (lt) | 2012-09-10 | 2019-07-10 | Reata Pharmaceuticals, Inc. | Oleanolio rūgšties c17-alkandiilo ir alkendiilo dariniai bei jų panaudojimo būdai |
BR112015005200B1 (pt) * | 2012-09-10 | 2022-07-05 | Reata Pharmaceuticals, Inc | Composto derivado de c17-heteroaril de ácido oleanólico, composição farmacêutica compreendendo o referido composto e uso do mesmo |
US9796752B2 (en) | 2013-03-19 | 2017-10-24 | Daiichi Sankyo Company, Limited | Terpenoid derivatives |
UY39092A (es) | 2013-04-24 | 2021-03-26 | Abbvie Inc | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso |
NZ744036A (en) | 2013-08-23 | 2020-09-25 | Reata Pharmaceuticals Inc | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
CN104861028A (zh) * | 2014-02-24 | 2015-08-26 | 上海兰蒂斯生物医药科技有限公司 | 新型熊果酸衍生物、其制备方法及其应用 |
CN104861027A (zh) * | 2014-02-24 | 2015-08-26 | 上海兰蒂斯生物医药科技有限公司 | 新型齐墩果酸衍生物、其制备方法及其应用 |
US9896475B2 (en) | 2014-08-26 | 2018-02-20 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
US10189791B2 (en) | 2014-08-26 | 2019-01-29 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
KR20170055482A (ko) | 2014-09-10 | 2017-05-19 | 다이이찌 산쿄 가부시키가이샤 | 안질환 치료용 및 예방용 서방성 의약 조성물 |
EP3212195A4 (en) * | 2014-10-31 | 2018-06-06 | The Regents of The University of California | Compositions and methods for treating hiv-associated cognitive dysfunction |
CA2974726C (en) | 2015-02-12 | 2023-09-19 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
EP3353190B1 (en) | 2015-09-23 | 2021-03-17 | Reata Pharmaceuticals, Inc. | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses |
CA3007744C (en) * | 2015-12-10 | 2022-05-17 | Universitat Fur Bodenkultur Wien | Compositions and methods for the diagnosis and treatment of bone fractures and disorders |
CN105820207A (zh) * | 2016-03-24 | 2016-08-03 | 庄立 | 一种茴拉西坦的药物组合物及其抗氧化作用 |
CA3042123A1 (en) | 2016-11-08 | 2018-05-17 | Reata Pharmaceuticals, Inc. | Methods of treating alport syndrome using bardoxolone methyl or analogs thereof |
TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物 |
CA3075023A1 (en) | 2017-09-14 | 2019-03-21 | Phoenix Biotechnology, Inc. | Method and improved neuroprotective composition for treating neurological conditions |
CA3075729A1 (en) | 2017-09-14 | 2019-03-21 | Phoenix Biotechnology, Inc. | Use of oleandrin to treatn viral infection |
US11993574B2 (en) | 2018-06-15 | 2024-05-28 | Reata Pharmaceuticals, Inc | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma |
US20220017566A1 (en) * | 2018-09-28 | 2022-01-20 | Sichuan Haisco Pharmaceutical Co., Ltd. | Terpinoid derivatives and uses thereof |
US20230023332A1 (en) * | 2019-11-27 | 2023-01-26 | Lunan Pharmaceutical Group Corporation | Olean-phenylacrylamide derivative, method for preparing same, and use thereof |
KR20220116209A (ko) * | 2019-12-19 | 2022-08-22 | 리아타 파마슈티컬즈, 아이엔씨. | C-17에서 질소 기반 치환기를 갖는 합성 트리테르페노이드 및 이의 사용 방법 |
MX2020009095A (es) | 2020-03-31 | 2022-07-28 | Phoenix Biotechnology Inc | Metodo y composiciones para el tratamiento de infeccion por coronavirus. |
EP4009981B1 (en) | 2020-03-31 | 2023-08-16 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
IL298008A (en) | 2020-05-09 | 2023-01-01 | Reata Pharmaceuticals Holdings Llc | Methods for treating covid-19 with the help of bardoxolone methyl or its analogs |
AU2021397631A1 (en) | 2020-12-11 | 2023-07-20 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
MX2023008454A (es) | 2021-01-18 | 2023-08-07 | Reata Pharmaceuticals Inc | Derivados sintéticos de ácido ursólico y métodos de uso de estos. |
CN113603743B (zh) * | 2021-08-06 | 2022-07-15 | 南通大学 | 一类具有联合治疗作用的cddo/川芎嗪醇杂合物及其制备方法和用途 |
CN117050134A (zh) * | 2022-05-05 | 2023-11-14 | 中国科学院上海有机化学研究所 | 酰胺化合物的合成及其用途 |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5555153Y2 (el) | 1975-03-19 | 1980-12-20 | ||
NZ191586A (en) | 1978-10-10 | 1981-10-19 | Sterling Drug Inc | Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions |
US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
DE3587500T2 (de) | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
RU1787160C (ru) | 1986-12-24 | 1993-01-07 | Эли Лилли Энд Компани | Способ получени иммуноглобулинового конъюгата |
IL89258A0 (en) | 1988-02-16 | 1989-09-10 | Lilly Co Eli | 2',3'-dideoxy-2',2'-difluoro-nucleosides |
US5064823A (en) | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
CA2004695C (en) | 1988-12-12 | 1999-08-10 | Rosanne Bonjouklian | Phospholipid nucleosides |
JPH05505815A (ja) | 1990-04-04 | 1993-08-26 | ニユコメド・イメージング・アクシエセルカペト | ヌクレオシド誘導体 |
SE502569C2 (sv) | 1991-05-31 | 1995-11-13 | British Tech Group | Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit |
UA41261C2 (uk) | 1992-06-22 | 2001-09-17 | Елі Ліллі Енд Компані | Спосіб одержання збагачених бета-аномером нуклеозидів |
YU43193A (sh) | 1992-06-22 | 1997-01-08 | Eli Lilly And Company | 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi |
US5401838A (en) | 1992-06-22 | 1995-03-28 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5426183A (en) | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5606048A (en) | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
DE4308042C2 (de) | 1993-03-13 | 2000-10-12 | Alstom Energy Syst Gmbh | Wälzmühle |
US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
US5972703A (en) | 1994-08-12 | 1999-10-26 | The Regents Of The University Of Michigan | Bone precursor cells: compositions and methods |
US5521294A (en) | 1995-01-18 | 1996-05-28 | Eli Lilly And Company | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides |
WO1998000173A2 (en) | 1996-07-03 | 1998-01-08 | Pharmacia & Upjohn Company | Targeted drug delivery using sulfonamide derivatives |
ATE236188T1 (de) | 1997-01-24 | 2003-04-15 | Conpharma As | Gemcitabin-derivate |
US20050276836A1 (en) | 1997-06-11 | 2005-12-15 | Michelle Wilson | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents |
US5965119A (en) | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
US6485756B1 (en) | 1999-04-06 | 2002-11-26 | Collaborative Technologies, Inc. | Stable, homogeneous natural product extracts containing polar and apolar fractions |
EP1591437B1 (en) | 1999-05-14 | 2009-11-25 | Nereus Pharmaceuticals, Inc. | Interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators |
EP1105730B1 (en) | 1999-06-25 | 2008-01-23 | Roche Diagnostics Operations, Inc. | Enzyme inhibition immunoassay |
US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
JP2001240573A (ja) * | 2000-03-01 | 2001-09-04 | Meiji Seika Kaisha Ltd | トリテルペン誘導体及び肝疾患治療剤 |
WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
JP2004509972A (ja) | 2000-09-29 | 2004-04-02 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 酵母に対する殺真菌活性を有するトリテルペン |
WO2002026762A1 (en) | 2000-09-29 | 2002-04-04 | Regents Of The University Of Minnesota | Triterpenes having antibacterial activity |
US6951847B2 (en) | 2000-09-29 | 2005-10-04 | Regents Of The University Of Minnesota | Methods of treating fungal infections using lupeol |
US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
AU2002243246A1 (en) | 2000-11-28 | 2002-06-24 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
AU2002308701A1 (en) | 2001-05-14 | 2002-11-25 | University Of Maryland, Baltimore | Novel alanine transaminase enzyme and methods of use |
KR20050044570A (ko) | 2001-11-23 | 2005-05-12 | 추가이 세이야쿠 가부시키가이샤 | 종양 표적 효소의 동정 방법 |
EP1465615B1 (en) | 2002-01-15 | 2012-08-01 | Trustees of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
CA2473799A1 (en) | 2002-01-18 | 2003-07-31 | Regents Of The University Of Minnesota | Triterpene quaternary salts as biologically active surfactants |
CA2485565A1 (en) * | 2002-05-13 | 2004-08-05 | Trustees Of Dartmouth College | Inhibitors and methods of use thereof |
US7265096B2 (en) | 2002-11-04 | 2007-09-04 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
WO2004089357A2 (en) | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
WO2005042002A2 (en) | 2003-10-30 | 2005-05-12 | Entelos, Inc. | Treatment of rhematoid arthritis with flip antagonists |
WO2005046732A2 (en) | 2003-11-04 | 2005-05-26 | THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH | Methods and compositions for the inhibition of hiv-1 replication |
ZA200604862B (en) | 2003-12-22 | 2007-10-31 | Alcon Inc | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
US20060258752A1 (en) | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
CN1272340C (zh) * | 2004-07-14 | 2006-08-30 | 中国药科大学 | 齐墩果酸偶联衍生物及其药物用途 |
CA2579231C (en) | 2004-09-07 | 2018-07-10 | Pacific Arrow Limited | Anti-tumor compounds with angeloyl groups |
CN101235071B (zh) * | 2004-12-29 | 2013-02-06 | 浙江大学 | 一类双烯齐墩果酸五环三萜类衍生物及用途 |
JP2006347952A (ja) * | 2005-06-16 | 2006-12-28 | Yoshihiro Futamura | リパーゼ活性化作用を呈するアントラキノン誘導体、それからなる抗肥満薬、食品製剤及び化粧品 |
WO2007005879A2 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
DE102005041613A1 (de) | 2005-09-01 | 2007-03-08 | Ergonex Pharma Gmbh | Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom |
WO2007069895A1 (en) | 2005-12-12 | 2007-06-21 | Mosamedix B.V. | Annexin derivatives suitable for pretargeting in therapy and diagnosis |
US20070232577A1 (en) | 2006-03-23 | 2007-10-04 | Advanced Life Sciences, Inc. | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin |
US20070249561A1 (en) | 2006-04-25 | 2007-10-25 | Taylor Bradley K | Pharmacological method for treatment of neuropathic pain |
JP5610766B2 (ja) | 2006-06-27 | 2014-10-22 | ウェリントン ラボラトリーズ インコーポレイティッド | グリチルレチン酸誘導体 |
CN101117348B (zh) * | 2006-08-01 | 2010-12-29 | 浙江海正药业股份有限公司 | A环和c环多氧化取代的五环三萜及其制备方法和用途 |
WO2008016095A1 (fr) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE |
JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
WO2008063318A2 (en) | 2006-10-12 | 2008-05-29 | The Texas A & M University System And Safe Et Al | Betulinic acid, derivatives and analogs thereof and uses therefor |
US8299046B2 (en) | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
JP2010510243A (ja) | 2006-11-17 | 2010-04-02 | トラスティーズ オブ ダートマス カレッジ | 三環系−ビス−エノン(tbe)の合成および生物学的活性 |
HRP20220902T3 (hr) | 2007-02-08 | 2022-10-14 | Biogen Ma Inc. | Pripravci i njihova upotreba u liječenju multiple skleroze |
WO2008111497A1 (ja) | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
US20080254055A1 (en) | 2007-04-11 | 2008-10-16 | John Erich Oblong | Compositions for Regulation of Hair Growth |
WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
WO2009023845A2 (en) | 2007-08-15 | 2009-02-19 | The Board Of Regents Of The University Of Texas System | Combination therapy with synthetic triterpenoids and gemcitabine |
US9012439B2 (en) | 2007-10-29 | 2015-04-21 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
CA3062806C (en) | 2008-01-11 | 2022-09-13 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
TW201004627A (en) | 2008-04-18 | 2010-02-01 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
KR101782020B1 (ko) | 2008-04-18 | 2017-09-26 | 리타 파마슈티컬스 잉크. | 산화방지성 염증 조절제 c-17 일치된 올레아놀산 유도체 |
ES2703274T3 (es) | 2008-04-18 | 2019-03-07 | Reata Pharmaceuticals Inc | Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17 |
TWI442925B (zh) | 2008-04-18 | 2014-07-01 | Reata Pharmaceuticals Inc | 抗氧化性發炎調節劑:c-環飽和之齊墩果酸衍生物 |
CA2721665C (en) | 2008-04-18 | 2017-01-24 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
JP2010016572A (ja) * | 2008-07-02 | 2010-01-21 | Fujitsu Ltd | 無線通信装置及びシステム |
AU2009274037B2 (en) | 2008-07-22 | 2015-07-09 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
WO2010053817A1 (en) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
SI3254675T1 (sl) | 2009-02-13 | 2019-08-30 | Reata Pharmaceuticals, Inc. | Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem |
WO2010127029A1 (en) | 2009-05-01 | 2010-11-04 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
PL2558105T3 (pl) | 2010-04-12 | 2020-04-30 | Reata Pharmaceuticals, Inc. | Metylowany bardoksolon do leczenia otyłości |
WO2011140078A1 (en) | 2010-05-04 | 2011-11-10 | Concert Pharmaceuticals, Inc. | Synthetic triterpenoid derivatives |
CN102070697A (zh) | 2010-12-09 | 2011-05-25 | 中国药科大学 | 一种齐墩果酸衍生物、其制备方法及用途 |
EA025568B1 (ru) | 2010-12-17 | 2017-01-30 | Рита Фармасьютикалз, Инк. | Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления |
AU2012212509B2 (en) | 2011-01-31 | 2016-01-21 | ViiV Healthcare UK (No.4) Limited | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity |
WO2012125488A1 (en) | 2011-03-11 | 2012-09-20 | Reata Pharmaceuticals, Inc. | C4-monomethyl triterpenoid derivatives and methods of use thereof |
WO2012154554A1 (en) | 2011-05-06 | 2012-11-15 | Catabasis Pharmaceuticals, Inc. | Fatty acid triterpene derivatives and their uses |
RS61544B1 (sr) | 2012-04-27 | 2021-04-29 | Reata Pharmaceuticals Inc | Derivat 2,2-difluoropropionamida metil bardoksolona, njegove farmaceutske supstance i polimorfi za upotrebu za lečenje izvesnih stanja |
US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
WO2013169740A2 (en) | 2012-05-08 | 2013-11-14 | Trustees Of Dartmouth College | Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression |
EA032734B1 (ru) | 2012-05-29 | 2019-07-31 | Парион Сайэнс, Инк. | Дендримероподобные аминоамиды, обладающие активностью блокаторов натриевых каналов, для лечения сухости глаз и других заболеваний слизистых оболочек |
WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
LT2892912T (lt) | 2012-09-10 | 2019-07-10 | Reata Pharmaceuticals, Inc. | Oleanolio rūgšties c17-alkandiilo ir alkendiilo dariniai bei jų panaudojimo būdai |
BR112015005200B1 (pt) | 2012-09-10 | 2022-07-05 | Reata Pharmaceuticals, Inc | Composto derivado de c17-heteroaril de ácido oleanólico, composição farmacêutica compreendendo o referido composto e uso do mesmo |
WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
MX2015003021A (es) | 2012-09-10 | 2015-11-09 | Abbvie Inc | Derivados de acido glicirretinico y metodos de uso de los mismos. |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
JP5972986B2 (ja) | 2012-09-28 | 2016-08-17 | アプライド ファーマシューティカル サイエンス インコーポレイテッド | Cddoエチルエステルの多形体及びその用途 |
CN102887936A (zh) | 2012-10-24 | 2013-01-23 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型 |
CN103788166A (zh) | 2012-10-30 | 2014-05-14 | 中国药科大学 | △13(18)-cddo衍生物、其制备方法与在制药中的用途 |
UY39092A (es) | 2013-04-24 | 2021-03-26 | Abbvie Inc | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso |
NZ744036A (en) | 2013-08-23 | 2020-09-25 | Reata Pharmaceuticals Inc | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
EP3097089B1 (en) | 2014-01-24 | 2021-02-24 | Reata Pharmaceuticals, Inc. | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
CA2974726C (en) | 2015-02-12 | 2023-09-19 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
EP3353190B1 (en) | 2015-09-23 | 2021-03-17 | Reata Pharmaceuticals, Inc. | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses |
CA3042123A1 (en) | 2016-11-08 | 2018-05-17 | Reata Pharmaceuticals, Inc. | Methods of treating alport syndrome using bardoxolone methyl or analogs thereof |
TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物 |
-
2009
- 2009-04-20 ES ES09732992T patent/ES2703274T3/es active Active
- 2009-04-20 RS RS20181534A patent/RS58392B1/sr unknown
- 2009-04-20 CA CA2721838A patent/CA2721838C/en active Active
- 2009-04-20 TW TW098113103A patent/TWI453023B/zh active
- 2009-04-20 PL PL09732992T patent/PL2276493T3/pl unknown
- 2009-04-20 EP EP09732992.4A patent/EP2276493B1/en active Active
- 2009-04-20 AU AU2009237579A patent/AU2009237579C1/en active Active
- 2009-04-20 EA EA201001555A patent/EA019263B1/ru unknown
- 2009-04-20 CN CN201410341447.5A patent/CN104177468B/zh active Active
- 2009-04-20 JP JP2011505259A patent/JP5529851B2/ja active Active
- 2009-04-20 WO PCT/US2009/041172 patent/WO2009129546A1/en active Application Filing
- 2009-04-20 SI SI200931910T patent/SI2276493T1/sl unknown
- 2009-04-20 CN CN200980123340.0A patent/CN102083442B/zh active Active
- 2009-04-20 PT PT09732992T patent/PT2276493T/pt unknown
- 2009-04-20 DK DK09732992.4T patent/DK2276493T3/da active
- 2009-04-20 US US12/426,778 patent/US8124799B2/en active Active
- 2009-04-20 NZ NZ588710A patent/NZ588710A/xx unknown
- 2009-04-20 MX MX2010011438A patent/MX2010011438A/es active IP Right Grant
- 2009-04-20 HU HUE09732992A patent/HUE041221T2/hu unknown
- 2009-04-20 LT LTEP09732992.4T patent/LT2276493T/lt unknown
- 2009-04-20 KR KR1020107025722A patent/KR101735807B1/ko active IP Right Grant
-
2010
- 2010-10-17 IL IL208758A patent/IL208758A/en active IP Right Grant
- 2010-10-25 ZA ZA2010/07586A patent/ZA201007586B/en unknown
- 2010-11-17 CO CO10143959A patent/CO6311071A2/es active IP Right Grant
-
2011
- 2011-06-27 HK HK11106595.3A patent/HK1152483A1/xx unknown
-
2012
- 2012-01-23 US US13/356,455 patent/US8440854B2/en active Active
-
2013
- 2013-04-11 US US13/861,208 patent/US9102681B2/en active Active
-
2015
- 2015-03-24 HK HK15103002.3A patent/HK1202552A1/xx unknown
- 2015-06-29 US US14/753,297 patent/US9670147B2/en active Active
-
2017
- 2017-06-06 US US15/615,393 patent/US10093614B2/en active Active
-
2018
- 2018-08-28 US US16/115,028 patent/US10556858B2/en active Active
- 2018-12-06 HR HRP20182060TT patent/HRP20182060T1/hr unknown
-
2019
- 2019-02-13 CY CY20191100194T patent/CY1121586T1/el unknown
-
2020
- 2020-02-10 US US16/786,429 patent/US11091430B2/en active Active
-
2021
- 2021-07-09 US US17/305,537 patent/US11919838B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121586T1 (el) | Αντιοξειδωτικοι ρυθμιστες της φλεγμονης: παραγωγα ελαιανολικου οξεος με αμινικη και αλλες τροποποιησεις στο c-17 | |
CY1118475T1 (el) | Αντιοξειδωτικοι ρυθμιστες φλεγμονης: c-17 ομολογοποιημενα παραγωγα ολεανολικου οξεος | |
EA201001488A1 (ru) | Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с сатурацией в с-кольце | |
CY1121265T1 (el) | Παραγωγα πιπεριδινονης ως αναστολεις της mdm2 για την θεραπευτικη αγωγη του καρκινου | |
CY1118048T1 (el) | Αντι-ιικες ενωσεις | |
CY1119762T1 (el) | C-17-ετεροαρυλικα παραγωγα ελαιολικου οξεος και μεθοδοι χρησης αυτων | |
PH12015500491A1 (en) | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof | |
MX348862B (es) | Derivados c4-monometil triterpenoides y sus metodos de uso. | |
CY1114689T1 (el) | C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
ECSP11010754A (es) | Derivados de triazol útiles para el tratamiento de enfermedades | |
CY1115043T1 (el) | Φαρμακευτικο σκευασμα | |
UA109667C2 (xx) | Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази | |
EA200901612A1 (ru) | Противовоспалительные соединения замещенных циклобутендионов | |
EA201170722A1 (ru) | Лактамы в качестве ингибиторов бета-секретазы | |
MA33948B1 (fr) | Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques. | |
CY1115673T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν 2-οξο-1-πυρρολιδινο παραγωγα | |
MX360330B (es) | Regimen de administracion para nitrocatecoles. | |
CY1111914T1 (el) | Μεθοδος συνθεσης της ιβαβραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ | |
CY1114493T1 (el) | Διαδικασια για την παρασκευη μιας ενωσης χρησιμης ως αναστολεα της tafia | |
EA201270302A1 (ru) | Безводные формы производных пиридина | |
UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
CO6612239A2 (es) | Derivados de ácido carboxílico que comprenden un anillo de oxazolopiridina 2,5-sustituido | |
CY1113983T1 (el) | Νεα μεθοδος συνθεσης της ιβαμπραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ | |
CY1112855T1 (el) | Παραγωγα των πυρρολοπυριδινο-2-καρβοξαμιδιων, η παρασκευη τους και η θεραπευτικη εφαρμογη τους |